Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-Blind, Multidose, Placebo-Controlled, Randomized, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 for Patients With Brain Contusion

NCT03954041 is registered in ClinicalTrials.gov with Remedy Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03954041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03954041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-Blind, Multidose, Placebo-Controlled, Randomized, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 for Patients With Brain Contusion
Lead sponsor
Remedy Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 6, 2019
Completion date
June 27, 2023
Enrollment
92 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

brain contusion